Does magnesium help with weight loss?

Barely. The largest review, a 2026 meta-analysis of 78 randomized trials in 5226 adults, found magnesium supplements lowered body weight by 1.5 lb (0.70 kg) against control, with a confidence interval from 0.2 to 2.9 lb (0.09 to 1.30 kg). Weight was a secondary outcome in those trials, and the authors call the effects modest and of uncertain clinical relevance. The same review found no significant change in BMI, waist, hips or body fat percentage.

Myth. Magnesium does not strip body fat. In the 2026 review, body fat percentage was the one body measure graded high certainty, and it changed by minus 0.02 points, with an interval from minus 0.46 to plus 0.43. That is a firm null.

What the trials found

The newest and largest review

The 2026 meta-analysis pooled trials in adults aged 23 to 73, with average BMI between 22 and 39. Most trials gave 300 mg a day or more for 12 weeks or longer. Body weight fell by 1.5 lb (0.70 kg), rated moderate certainty. Waist changed by minus 0.39 in (0.98 cm), with an interval from minus 2.02 to plus 0.05, and BMI by minus 0.65, with an interval from minus 1.49 to plus 0.19. Neither reached significance.

The weight loss appeared only in some subgroups. These were trials shorter than 12 weeks, doses under 300 mg a day, organic forms of magnesium, women and people aged 50 or older. Those were subgroup findings, not the overall result. A supplement that works better at lower doses and in shorter trials is a weak basis for a weight plan.

Two earlier reviews that disagree a little

A 2021 dose-response meta-analysis of 32 trials, at 48 to 450 mg a day for 6 to 24 weeks, found BMI fell by 0.21 kg/m2, with an interval from 0.001 to 0.41. Heterogeneity was very high, at 89.5 percent, and the upper end of that interval sits almost at zero. Body weight, waist and body fat did not change overall. They did change in subgroups of people with insulin resistance disorders, high blood pressure, obesity or low magnesium at the start, and in women. The abstract gives no sizes for those subgroup effects.

A second 2021 meta-analysis, of 28 trials in 2013 people, found no significant change in body weight, waist, BMI or body fat overall. It overlaps heavily with the 32-trial review. In 12 trials of 997 people with a BMI over 30, waist circumference fell by 0.82 in (2.09 cm), with an interval from 0.03 to 1.6 in (0.07 to 4.12 cm).

People with diabetes, prediabetes or polycystic ovary syndrome

In type 2 diabetes, a pooled analysis of five trials found body weight changed by minus 0.02 lb (0.01 kg), with an interval from minus 0.36 to plus 0.33. BMI and waist did not change either. A 12-week trial of 250 mg of magnesium oxide a day in 86 people with prediabetes in Isfahan, Iran, found no difference from placebo in body measurements. A two-month trial of the same dose in 40 women aged 15 to 35 with polycystic ovary syndrome found none either.

The one positive trial was in a narrow group. In 118 obese, prediabetic patients with low blood magnesium and reduced kidney function, 365 mg a day for three months cut waist circumference by 4.8 per cent against a rise of 0.55 percent on placebo. The share with obesity fell by 15.7 percent against 8.2 percent, and that difference did not reach significance. The dose was above the 350 mg upper limit for supplements.

Unsettled. Where an effect shows up, it shows up in people who were short of magnesium, insulin resistant or obese to begin with, and in subgroups rather than in whole trials. Nobody has run a trial designed to test exactly those people with weight as the main outcome, so whether correcting a shortfall helps weight is still an open question.

The long cohort

Spectacular numbers come from observational data. In the CARDIA cohort, 5115 Americans aged 18 to 30 at the start were followed for 30 years. Those in the highest fifth of magnesium intake had about half the risk of developing obesity of those in the lowest fifth, a hazard ratio of 0.49, with an interval from 0.40 to 0.60. Intake from food tracks whole grains, nuts, legumes and vegetables, and the study cannot separate magnesium from diet quality.

Who should be careful

The upper limit for supplemental magnesium is 350 mg a day for adults, and 65 to 350 mg for children and teenagers depending on age. Magnesium in food does not count toward it. Trials in one of the 2021 reviews used up to 450 mg a day, and the kidney-patient trial 365 mg, both above it. High doses from supplements often cause diarrhea, which can come with nausea and abdominal cramping.

Magnesium can interact with oral bisphosphonates and with tetracycline and quinolone antibiotics.

Not for everyone. If your kidney function is reduced, the risk of magnesium toxicity rises, because the kidneys can no longer clear the excess. A weight-loss dose of magnesium is then a question for your doctor, and so is any dose if you take one of the medicines above.

What expert bodies say

We found no agency position that recommends magnesium for weight loss. The EU register of health claims authorizes one claim relevant here, that magnesium contributes to normal energy-yielding metabolism. It holds no authorized claim linking magnesium to body weight. A label that mentions energy metabolism is making a different claim from weight loss, even when the packaging suggests otherwise.

How we searched

What would change this answer

• A pre-registered trial of magnesium alone in people with low magnesium status and obesity, with weight or fat mass as the main outcome, running six months or longer. We found no such trial registered on ClinicalTrials.gov.
• The subgroup numbers from the 2021 reviews. They say weight moved in people with deficiency, insulin resistance or obesity, and without the sizes nobody can judge whether that movement matters.

For what magnesium does, how much you need and where to find it in food, see the magnesium guide.

Sources

1. ev-mgwt-01 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials · n = 5226
   Mg supplementation significantly reduced body weight (weighted mean difference [WMD]: -0.70 kg; 95% confidence interval [CI]: -1.30, -0.09)
   
   Who: adults aged 23 to 73 in randomized controlled trials of magnesium supplementation, mean BMI 22 to 39, searched up to May 2026
   Effect: body weight WMD -1.5 lb (95% CI -2.9 to -0.2; metric: -0.70 kg, -1.30 to -0.09); most trials 300 mg/day or more and 12 weeks or more
   Certainty: Weight was a secondary cardiometabolic outcome; authors call effects modest and of uncertain clinical relevance.
   Nutrients, 2026 · checked 2026-10-07 · we read the abstract
2. ev-mgwt-02 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials · n = 78 trials
   In contrast, no substantial differences were observed in HC (WMD: −0.60 cm, 95% CI: −1.79, 0.59), WC (WMD: −0.98 cm, 95% CI: −2.02, 0.05), BMI (WMD: −0.65 kg/m2, 95% CI: −1.49, 0.19), or BFP (WMD: −0.02%, 95% CI: −0.46, 0.43)
   
   Who: adults in randomized controlled trials of magnesium supplementation
   Effect: WC WMD -0.39 in (95% CI -0.8 to 0.02; metric: -0.98 cm, -2.02 to 0.05); BMI WMD -0.65 kg/m2 (95% CI -1.49 to 0.19); body fat WMD -0.02% (95% CI -0.46 to 0.43); hip WMD -0.24 in (95% CI -0.7 to 0.23; metric: -0.60 cm, -1.79 to 0.59)
   Certainty: Body fat result rated high certainty by GRADE, so the null on fat is the firmest finding.
   Nutrients, 2026 · checked 2026-10-07 · we read the fulltext
3. ev-mgwt-03 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials, GRADE assessment · n = 78 trials
   High-certainty evidence was identified for BFP and TNF-α. Moderate-certainty evidence was observed for BW, BMI, HC, HbA1c, HOMA-IR, DBP, IL-6, CRP, and Cr.
   
   Who: 78 randomized controlled trials of magnesium supplementation
   Effect: GRADE: body fat percentage high; body weight and BMI moderate; waist circumference low
   Certainty: GRADE ratings are the review authors' own judgements.
   Nutrients, 2026 · checked 2026-10-07 · we read the fulltext
4. ev-mgwt-04 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials, subgroup analysis · n = 78 trials
   Subgroup analyses indicated that reductions in BW were observed among participants who received Mg supplementation in studies with intervention durations < 12 weeks, Mg doses < 300 mg/day, organic Mg formulations, high Mg bioavailability, female participants, and individuals aged ≥50 years.
   
   Who: subgroups of randomized controlled trials of magnesium supplementation
   Effect: body weight reductions limited to subgroups: duration under 12 weeks, dose under 300 mg/day, organic Mg, high bioavailability, women, age 50 or older
   Certainty: Subgroup findings, not the overall result.
   Nutrients, 2026 · checked 2026-10-07 · we read the fulltext
5. ev-mgwt-05 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials · n = 32 trials (22 for BMI)
   Magnesium supplementation resulted in a great reduction in BMI [Weighted Mean Difference (WMD): -0.21 kg/m2, 95% CI: -0.41, -0.001, P = 0.048, I2 = 89.5%, n = 22], which was mainly driven by the effect among those with magnesium deficiency, insulin resistance related disorders, and obesity at baseline.
   
   Who: adults in randomized controlled trials, magnesium 48 to 450 mg/day for 6 to 24 weeks
   Effect: BMI WMD -0.21 kg/m2 (95% CI -0.41 to -0.001), I2 89.5%; body weight, WC, body fat and WHR not significant
   Certainty: Very high heterogeneity; upper CI bound almost zero.
   Crit Rev Food Sci Nutr, 2021 · checked 2026-10-07 · we read the abstract
6. ev-mgwt-06 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials, subgroup analysis · n = 32 trials
   However, the change in body weight, and WC was significant in subgroups of participants with insulin resistance related disorders, hypertension, obesity, magnesium deficiency at baseline, and females.
   
   Who: subgroups of adults in randomized controlled trials of magnesium supplementation
   Effect: significant body weight and WC change only in subgroups; overall not significant
   Certainty: Subgroup findings; effect sizes for subgroups not in abstract.
   Crit Rev Food Sci Nutr, 2021 · checked 2026-10-07 · we read the abstract
7. ev-mgwt-07 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials · n = 2013
   There were no significant changes in anthropometric indices after Mg supplementation in the overall analysis.
   
   Who: participants in randomized controlled trials of magnesium supplementation, searched to February 2020
   Effect: no significant change in body weight, WC, BMI or body fat percentage overall; non-linear dose-response not significant
   Certainty: Overlaps heavily with the 32-trial review published the same year.
   Br J Nutr, 2021 · checked 2026-10-07 · we read the abstract
8. ev-mgwt-08 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials, subgroup analysis · n = 997
   However, subgroup analysis revealed that Mg supplementation decreases WC in subjects with BMI > 30 kg/m2 (obese) (twelve trials, n 997 participants; weighted mean difference = –2·09 cm, 95 % CI –4·12, –0·07, P = 0·040; I2 = 0 %).
   
   Who: subjects with BMI above 30 kg/m2
   Effect: WC WMD -0.82 in (95% CI -1.6 to -0.03; metric: -2.09 cm, -4.12 to -0.07), I2 0%
   Certainty: Subgroup result; upper CI bound near zero.
   Br J Nutr, 2021 · checked 2026-10-07 · we read the abstract
9. ev-mgwt-09 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials · n = 5 trials
   The pooled analysis of five RCTs showed that Mg supplementation did not affect body weight (WMD: - 0.01 kg, 95% CI: - 0.36 to 0.33), BMI (WMD: - 0.07, 95% CI: - 0.18 to 0.04), and waist circumference (WMD: 0.12, 95% CI: - 1.24 to 1.48) in T2DM patients compared to the control groups of the patients who received placebo.
   
   Who: patients with type 2 diabetes in randomized controlled trials
   Effect: body weight WMD -0.02 lb (95% CI -0.79 to 0.73; metric: -0.01 kg, -0.36 to 0.33); BMI WMD -0.07 (95% CI -0.18 to 0.04); WC WMD 0.12 (95% CI -1.24 to 1.48)
   Certainty: Only five trials.
   Biol Trace Elem Res, 2021 · checked 2026-10-07 · we read the abstract
10. ev-mgwt-10 · Randomized controlled trial(s) · randomized double-blind placebo-controlled trial · n = 86
    The mean changes of HOMA-IR index, total cholesterol, LDL-cholesterol, triglyceride, uric acid and C-reactive protein levels as well as anthropometric indices and blood pressure in supplemented and placebo groups did not differ significantly.
    
    Who: people with prediabetes, Isfahan, Iran; magnesium oxide 250 mg/day for 12 weeks
    Effect: no significant difference in mean change of anthropometric indices versus placebo
    Certainty: Small, single center; HDL rose, other markers unchanged.
    Sci Rep, 2022 · checked 2026-10-07 · we read the abstract
11. ev-mgwt-11 · Randomized controlled trial(s) · randomized double-blind placebo-controlled trial · n = 118
    At the end of follow-up, insulin resistance (-24.5 vs. -8.2%, P = 0.007), HOMA-IR index (-31.9 vs. -3.3%, P < 0.001), hemoglobin A1c (-6.6 vs. -0.16%, P < 0.001), insulin (-29.6 vs. -2.66%, P < 0.001), waist circumference (-4.8 vs. 0.55%, P < 0.001) and uric acid (-0.8 vs. 2.2%, P = 0.004) were significantly decreased in terms of mean changes
    
    Who: hypomagnesemic, prediabetic, obese patients with eGFR 30 to 90 ml/min/1.73m2; 365 mg oral magnesium daily (n=57) vs placebo (n=61)
    Effect: WC -4.8% vs +0.55% (P<0.001); obesity -15.7% vs -8.2% (P=0.131)
    Certainty: Selected group with deficiency and kidney disease; 128 enrolled, 118 analyzed; 365 mg exceeds the 350 mg supplemental UL.
    Kidney Blood Press Res, 2017 · checked 2026-10-07 · we read the abstract
12. ev-mgwt-12 · Randomized controlled trial(s) · triple-blind randomized clinical trial · n = 40
    We could not find any significant difference in anthropometric parameters as well as the mean systolic and diastolic blood pressures before and after intervention between the two groups.
    
    Who: women aged 15 to 35 with PCOS; magnesium oxide 250 mg/day for 2 months
    Effect: no significant difference in anthropometric parameters between groups
    Certainty: Very small trial.
    Biol Trace Elem Res, 2024 · checked 2026-10-07 · we read the abstract
13. ev-mgwt-13 · Observational data · prospective cohort study · n = 5115
    The multivariable-adjusted hazard ratios (95% confidence interval) from quintile 1 (Q1) (lowest intake group) to quintile 5 (Q5) (highest intake group) were 1 (referent), 0.86 (0.74, 1.00), 0.83 (0.71, 0.97), 0.55 (0.46, 0.66), and 0.49 (0.40, 0.60); P for trend < 0.01.
    
    Who: American young adults aged 18 to 30 at baseline (CARDIA), followed 30 years
    Effect: incident obesity HR Q5 vs Q1 0.49 (95% CI 0.40 to 0.60); 1675 cases
    Certainty: Diet-based magnesium tracks whole grains, nuts, legumes and vegetables; cannot separate magnesium from diet quality.
    Eur J Nutr, 2020 · checked 2026-10-07 · we read the abstract
14. ev-mgwt-14 · Position of an expert body · regulatory register entry · n = —
    POL-HC-6403 Magnesium Magnesium contributes to normal energy-yielding metabolism Authorised
    
    Who: foods and supplements sold in the EU
    Effect: authorized claim: normal energy-yielding metabolism; no weight claim in the register
    Certainty: Energy metabolism claims are often marketed as weight claims; they are not the same.
    EU Register on nutrition and health claims (European Commission) · checked 2026-10-07 · we read the dataset
15. ev-mgwt-15 · Position of an expert body · agency fact sheet · n = —
    The Tolerable Upper Intake Level for supplemental magnesium is 350 mg for adults, and it ranges from 65 to 350 mg for children and adolescents, depending on age.
    
    Who: Adults; children and adolescents 65 to 350 mg depending on age
    Effect: UL for supplemental magnesium 350 mg/day (adults); food magnesium not counted
    Certainty: Trials in the 32-trial review used up to 450 mg/day, and the kidney-patient trial 365 mg/day, above this limit.
    NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section
16. ev-mgwt-16 · Position of an expert body · agency fact sheet · n = —
    However, high doses of magnesium from dietary supplements or medications often result in diarrhea that can be accompanied by nausea and abdominal cramping
    
    Who: people taking high-dose magnesium supplements or medications
    Effect: diarrhea, which can come with nausea and abdominal cramping
    Certainty: Agency safety statement.
    NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section
17. ev-mgwt-17 · Position of an expert body · agency fact sheet · n = —
    The risk of magnesium toxicity increases with impaired renal function or kidney failure because the ability to remove excess magnesium is reduced or lost
    
    Who: People with impaired renal function or kidney failure
    Effect: higher risk of magnesium toxicity
    Certainty: Applies to anyone with reduced kidney function.
    NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section
18. ev-mgwt-18 · Position of an expert body · agency fact sheet · n = —
    Magnesium may interact with certain medications, such as oral bisphosphonates, tetracyclines, and quinolone antibiotics.
    
    Who: people taking oral bisphosphonates, tetracyclines or quinolone antibiotics
    Effect: drug interactions with oral bisphosphonates, tetracyclines and quinolones
    Certainty: Listed interactions; the quote gives no dosing interval.
    NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section